Sotio, Inc. (Sotio)

Oncology Corporate Profile

HQ Location

180 Canal St., Suite 300
Boston, MA 2114

Company Description

SOTIO is an international biotechnology company developing new medical therapies, focusing on the treatment of cancer and autoimmunity diseases. The company conducts research concerning the actual platform of active cellular immunotherapy on the basis of dendritic cells, with the goal of significantly improving this treatment and making it accessible to patients. In SOTIO_†_s laboratory in Prague, equipped with state-of-the-art technology, leading scientists research the role of dendritic cells in the therapeutic activation of the immune system and work to verify its safety and efficacy through clinical trials. SOTIO has facilities in Europe, the United States, China and Russia

Website: http://www.sotio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
DCVAC/Pcacellular immunotherapyProstate cancerIII
DCVAC/LuCacellular immunotherapyNon Small Cell Lung Cancer (NSCLC)II
DCVAC/OvCacellular immunotherapyOvarian cancerII
RLI-15 platformimmunocytokineVarious cancer typesPreclinical
CYP0150super IL-15 cytokineVarious cancer typesPreclinicalCytune Pharma

View additional information on product candidates here »

Source


http://www.sotio.com

Recent News Headlines

There are no news items to display